Guess Who Picked Up Enstar Group Ltd (NASDAQ:ESGR) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Enstar Group Ltd (NASDAQ:ESGR)reported that Beck Mack & Oliver Llc. has picked up 806,092 of common stock as of 2017-04-28.
The acquisition brings the aggregate amount owned by Beck Mack & Oliver Llc. to a total of 806,092 representing less than 4.91% stake in the company.
For those not familiar with the company, Enstar Group Limited is an insurance group that offers capital release solutions and specialty underwriting capabilities through its network of group companies in Bermuda, the United States, the United Kingdom, Continental Europe, Australia and other international locations. The Company’s segments include Non-Life Run-Off, Atrium, StarStone, and Life and Annuities. The Non-life Run-off segment comprises the operations of its subsidiaries that are running off their property and casualty and other non-life lines of business. The Atrium segment underwrites specialist marine, energy, aerospace, non-marine and liability classes. The StarStone segment offers a range of property, casualty and specialty insurance products. The Life and Annuities Segment consists of the operations managing the Company’s closed-block of life and annuity business, and its life settlements business.
A glance at Enstar Group Ltd (NASDAQ:ESGR)’s key stats reveals a current market capitalization of 3.74 Billion based on 16.18 Million shares outstanding and a price at last close of $194.10 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2013-08-15 Lestrange picked up 500 at a purchase price of $136.44. This brings their total holding to 2,000 as of the date of the filing.
On the sell side, the most recent transaction saw Rajpal unload 343,487 shares at a sale price of $158.50. This brings their total holding to 322,061.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Enstar Group Ltd (NASDAQ:ESGR) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Here’s Who Picked Aehr Test Systems (NASDAQ:AEHR) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Aehr Test Systems (NASDAQ:AEHR) reported that Schneider John M. has picked up 145,218 of common stock as of 2017-04-28.
The acquisition brings the aggregate amount owned by Schneider John M. to a total of 145,218 representing less than 0.68% stake in the company.
For those not familiar with the company, Aehr Test Systems is engaged in the designing, manufacturing and marketing of advanced test and burn-in products to the semiconductor manufacturing industry. The Company manufactures and markets full wafer contact test systems, test during burn-in systems, test fixtures, die carriers and related accessories. The Company’s principal products are the Advanced Burn-In and Test System (ABTS), the FOX full wafer contact parallel test and burn-in systems, WaferPak full wafer contactor, the DiePak carrier and test fixtures. The Company develops, manufactures and sells systems, which are designed to reduce the cost of testing and to perform reliability screening, or burn-in, of complex logic devices, memory integrated circuits (ICs), sensors and optical devices. These systems can be used to perform parallel testing and burn-in of packaged ICs, singulated bare die or ICs still in wafer form.
A glance at Aehr Test Systems (NASDAQ:AEHR)’s key stats reveals a current market capitalization of 83.34 Million based on 16.79 Million shares outstanding and a price at last close of $4.76 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2015-08-17 Anderson picked up 1,500 at a purchase price of $2.22. This brings their total holding to 429,009 as of the date of the filing.
On the sell side, the most recent transaction saw Hendrickson unload 5,000 shares at a sale price of $4.83. This brings their total holding to 15,663.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Aehr Test Systems (NASDAQ:AEHR) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Why CytRx Corporation (NASDAQ:CYTR) Stock Could Keep Dropping
CytRx Corporation (NASDAQ:CYTR) shares were down 15.02% on Thursday to $0.685 and an additional 7.65% in after-hours trading to $0.632. The company has a market cap of $75.70 million at 117.32 million shares outstanding. Share prices have been trading in a 52-week range of $0.36 to $3.46.
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. It is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy.
The company is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi’s sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology.
Earlier this month, CytRx Corporation announced that an abstract describing results from its global Phase 3 clinical trial evaluating aldoxorubicin versus investigators’ choice in patients with relapsed and refractory soft tissue sarcomashas been selected for an oral presentation at the 2017 American Society of Clinical Oncology in June.
We look forward to presenting the more detailed and updated global Phase 3 results to the medical community at ASCO this year,” said Daniel Levitt, M.D., Ph.D., Chief Operating Officer and Chief Medical Officer of CytRx Corporation. “The Phase 3 trial and the combination trial of aldoxorubicin with ifosfamide continue to build on our prior studies showing the utility of aldoxorubicin as a treatment for patients with STS. These trials, together with our other clinical and pre-clinical studies of aldoxorubicin, will support our planned New Drug Application submission.”
However, the gains were quickly faded when CytRx Corporation recently announced a proposed public offering of its common stock that is subject to market conditions. The company plans to use the proceeds for working capital and general corporate purposes, including clinical and regulatory activities, new drug discovery activities, and possible future strategic transactions.
Also, there an be no assurance as to whether or when the offering may be consummated, or as to the actual size or terms of the offering. H.C. Wainwright & Co. is acting as exclusive placement agent for the offering.
DISCLAIMER: There is a substantial risk of loss with any speculative asset, especially small cap stocks. The opinions expressed are those of the author, and do not constitute recommendations to buy or sell a stock. Do your own research before committing capital.